Enantiomer specific pharmacokinetics of ibuprofen in preterm neonates with patent ductus arteriosus.

ABSTRACT:

Aims

Racemic ibuprofen is widely used for the treatment of preterm neonates with patent ductus arteriosus. Currently used bodyweight-based dosing guidelines are based on total ibuprofen, while only the S-enantiomer of ibuprofen is pharmacologically active. We aimed to optimize ibuprofen dosing for preterm neonates of different ages based on an enantiomer-specific population pharmacokinetic model.

Methods

We prospectively collected 210 plasma samples of 67 preterm neonates treated with ibuprofen for patent ductus arteriosus (median gestational age [GA] 26 [range 24-30] weeks, median body weight 0.83 [0.45-1.59] kg, median postnatal age [PNA] 3 [1-12] days), and developed a population pharmacokinetic model for S- and R-ibuprofen.

Results

We found that S-ibuprofen cleara

SUBMITTER: Engbers AGJ 

PROVIDER: S-EPMC7495289 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature